SCHEMBL2266623

SCHEMBL2266623

O=S(=O)(Cl)c1cc(S(=O)(=O)Cl)c(Cl)cc1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 10/20 0.42
CA2 P00918 10/20 0.42
CA4 P22748 5/20 0.42
CA12 O43570 4/20 0.42
CA6 P23280 4/20 0.42
CA5A P35218 4/20 0.42
CA7 P43166 4/20 0.42
CA9 Q16790 4/20 0.42
CA14 Q9ULX7 4/20 0.42
CA5B Q9Y2D0 4/20 0.42
CA3 P07451 3/20 0.42
TRPV4 Q9HBA0 2/20 0.41
TSHR P16473 4/20 0.39
HSD17B10 Q99714 4/20 0.39
HPGD P15428 2/20 0.39
CA13 Q8N1Q1 3/20 0.37
CISD1 Q9NZ45 1/20 0.37
CYP3A4 P08684 2/20 0.36
HSP90AA1 P07900 1/20 0.36
ALDH1A1 P00352 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29859022 0.88 HSD17B10 (0.46) CA1CA2CA4CA12CA6
SCHEMBL6894760 0.88 HSD17B10 (0.46) CA1CA2CA4CA12CA6
SCHEMBL5635695 0.86 TSHR (0.50) CA1CA2CA4CA12CA6
SCHEMBL4426923 0.83 TRPV4 (0.48) CA1CA2CA4CA12CA6
SCHEMBL1058912 0.81 ACHE (0.40) CA1CA2CA4CA12CA6
SCHEMBL1991714 0.80 TRPV4 (0.50) CA1CA2CA4CA12CA6
SCHEMBL15733474 0.78 CA1 (0.56) CA1CA2CA4CA12CA6
SCHEMBL15881406 0.78 CA1 (0.43) CA1CA2CA4CA12CA6
SCHEMBL9514425 0.77 CA1 (0.63) CA1CA2CA4CA12CA6
SCHEMBL17017265 0.77 TRPV4 (0.42) CA1CA2CA4CA12CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 CA1 2063/4885CA2 2818/4885CA4 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.